We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Thomas Hughes, Ph.D., has left Zafgen to become CEO at mTORC1 startup Navitor Pharmaceuticals. Hughes helmed Zafgen through a turbulent time in which it abandoned its lead candidate after patients died in a phase 3 study.
Navitor Pharmaceuticals announced the initiation of a Phase 1 clinical study with its lead pipeline candidate, NV-5138, for treatment-resistant depression (TRD).